What are Ginkgo Bioworks's total assets?

Ginkgo Bioworks (DNA) holds $1.0B in total assets, down 20.1% year over year.

How much debt does Ginkgo Bioworks have?

Ginkgo Bioworks carries $410.7M in total debt against $443.2M of shareholders' equity, a debt-to-equity ratio of 0.93.

How much cash does Ginkgo Bioworks have?

Ginkgo Bioworks holds $188.7M in cash and equivalents.

Can Ginkgo Bioworks cover its short-term obligations?

Its current ratio is 5.15 — current assets exceed current liabilities.

Where does Ginkgo Bioworks's balance sheet data come from?

Every line is extracted from Ginkgo Bioworks's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Ginkgo Bioworks DNA Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Cash and cash equivalents	$188.67M-11.2%	$212.37M+35.3%	$156.96M-37.6%	$251.35M-29.3%	$355.41M-41.3%
Restricted cash	$6.88M-84.8%	$45.17M+413%	$8.8M-19.6%	$10.95M+37.8%	$7.94M-82.0%
Accounts receivable, net	$19.82M-17.5%	$24.03M+12.1%	$21.43M-3.3%	$22.15M-15.7%	$26.29M+20.3%
Prepaid expenses and other current assets	$16.23M-35.0%	$24.96M+14.2%	$21.86M-16.6%	$26.21M+28.2%	$20.44M+9.1%
Assets held for sale	$3.21M-16.7%	$3.85M—	——	——	——
Trading assets	$179.22M—	——	——	——	——
Total current assets	$409.96M-13.1%	$471.84M-6.8%	$506.08M-3.2%	$523.03M-7.4%	$564.53M-6.3%
Property and equipment, net	$163.02M-2.6%	$167.37M-5.2%	$176.58M-5.2%	$186.35M-5.8%	$197.83M-2.9%
Accumulated depreciation	$189.38M+0.8%	$187.91M+3.2%	$182.08M+4.9%	$173.5M+6.2%	$163.42M+1.6%
Operating lease right-of-use assets	$353.8M-2.0%	$360.92M-2.0%	$368.21M-2.0%	$375.8M-2.0%	$383.39M-2.8%
Intangible assets, net	$48.86M-14.2%	$56.92M-7.5%	$61.52M-7.0%	$66.15M-3.8%	$68.76M-5.2%
Other non-current assets	$39.52M-16.2%	$47.17M+1.2%	$46.59M-0.9%	$47.02M+0.5%	$46.78M-15.5%
Equity method investments	$13.31M—	——	$27.81M—	——	——
Long-term investments	$14.7M-2.4%	$15.07M-50.1%	$30.18M-7.6%	$32.66M+1.5%	$32.17M-33.9%
Total investment securities	$229.59M-10.1%	$255.42M-27.2%	$350.8M+29.9%	$270.13M+32.1%	$204.5M—
Available-for-sale securities	$40.54M+169%	$15.07M-50.1%	$30.18M-7.6%	$32.66M+1.5%	$32.17M-33.9%
Gross loans	——	$500K—	——	——	——
Total assets	$1.03B-7.7%	$1.12B-5.8%	$1.19B-3.4%	$1.23B-4.8%	$1.29B-6.1%
Accrued expenses	$48.38M-27.2%	$66.46M-16.2%	$79.34M+38.6%	$57.23M-19.1%	$70.75M+8.2%
Deferred revenue	$14.91M-21.3%	$18.95M-24.9%	$25.24M-10.8%	$28.29M-15.9%	$33.65M+21.4%
Operating lease liabilities, current	——	$22.79M—	——	——	——
Finance Lease Liability, Current	——	$20K—	——	——	——
Contract liabilities	$77.9M+3.6%	$75.18M+1.5%	$74.07M-0.7%	$74.57M-7.2%	$80.38M-18.6%
Total current liabilities	$79.6M-17.1%	$95.97M-16.8%	$115.28M+19.2%	$96.72M-16.4%	$115.67M+7.8%
Operating lease liabilities, non-current	$410.7M-1.5%	$417.08M-1.4%	$422.87M-1.4%	$428.83M-1.3%	$434.56M-1.0%
Finance Lease Liabilities (Total)	——	$20K—	——	——	——
Operating Lease Liabilities (Total)	——	$439.87M—	——	——	——
Other non-current liabilities	$21.73M-5.0%	$22.88M+33.3%	$17.16M-4.4%	$17.94M+16.3%	$15.43M-6.9%
Total liabilities	$5.69M0.0%	$5.69M0.0%	$5.69M0.0%	$5.69M-34.0%	$8.62M-13.1%
Preferred stock	$0—	$0—	$0—	$0—	$0—
Common stock	15.8B0.0%	15.8B0.0%	15.8B0.0%	15.8B0.0%	15.8B+315,999,900%
Additional paid-in capital	$6.67B+0.3%	$6.66B+0.4%	$6.63B+0.4%	$6.6B+0.4%	$6.58B+0.3%
Retained earnings	-$6.23B-1.3%	-$6.15B-1.3%	-$6.07B-1.3%	-$5.99B-1.0%	-$5.93B-1.6%
Accumulated other comprehensive income (loss)	$1.19M-35.5%	$1.85M-7.3%	$2M+20.8%	$1.65M+294%	-$850K+52.9%
Total stockholders' equity	$443.15M-12.9%	$508.59M-9.1%	$559.78M-8.7%	$612.95M-5.3%	$647.43M-9.6%
Total liabilities and stockholders' equity	$1.03B-7.7%	$1.12B-5.8%	$1.19B-3.4%	$1.23B-4.8%	$1.29B-6.1%
Available-for-Sale Debt Securities - Amortized Cost	$179.18M—	——	$364.36M+6.5%	$342.22M—	——
Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year)	$179.18M—	——	——	——	——
Cash, Cash Equivalents, and Marketable Securities	$229.59M-10.1%	$255.42M—	——	——	——
Trading Securities in Marketable Securities	$13.31M—	——	$27.81M—	——	——
Available-for-Sale Debt Securities - Fair Value (Maturing 1 to 5 Years)	$40.54M—	——	——	——	——
Deferred Tax Assets and Other Non-Current Assets	$39.52M-16.2%	$47.17M+1.2%	$46.59M-0.9%	$47.02M+0.5%	$46.78M-15.5%
Equity Securities (FV-NI and No Readily Determinable FV) - Cost	$14.7M-2.4%	$15.07M-50.1%	$30.18M-7.6%	$32.66M+1.5%	$32.17M-33.9%
Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments	$13.31M—	——	$27.81M—	——	——
Equity Securities Without Readily Determinable Fair Value - Cumulative Impairment Loss	$91.81M—	——	$77.31M—	——	——
Equity Securities Without Readily Determinable Fair Value	$4.34M—	——	$4.34M—	——	——
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	$2.94M—	——	$2.98M+0.1%	$2.98M+9.5%	$2.72M—
Investments - Amortized Cost Basis	$13.31M-94.4%	$236.64M+751%	$27.81M-91.9%	$342.22M—	——
Net Investment in Lease	$353.8M-2.0%	$360.92M-2.0%	$368.21M-2.0%	$375.8M-2.0%	$383.39M-2.8%
Private debt held-for-investment, at amortized cost, net of valuation allowance – $3 and $4	$7.5M-22.7%	$9.7M-55.9%	$22M0.0%	$22M-11.6%	$24.9M-0.8%
Intangible assets — net	$48.86M—	——	$61.52M-7.0%	$66.15M-3.8%	$68.76M—
Other intangible assets—net	$48.86M-8.6%	$53.48M-13.1%	$61.52M-7.0%	$66.15M-3.8%	$68.76M-5.2%
Investments	$14.7M-2.4%	$15.07M-50.1%	$30.18M-7.6%	$32.66M+1.5%	$32.17M-33.9%
Operating lease right-of-use assets	$353.8M-2.0%	$360.92M-2.0%	$368.21M-2.0%	$375.8M-2.0%	$383.39M-2.8%
Other non-current assets	$39.52M-16.2%	$47.17M+1.2%	$46.59M-0.9%	$47.02M+0.5%	$46.78M-15.5%
Property, plant and equipment at cost	$352.4M-0.8%	$355.28M-0.9%	$358.65M-0.3%	$359.85M-0.4%	$361.25M-0.9%
Operating Lease Right-of-Use Assets in Other Assets	$353.8M-2.0%	$360.92M-2.0%	$368.21M-2.0%	$375.8M-2.0%	$383.39M-2.8%
Software and Technology Licenses, Net	$39.52M-16.2%	$47.17M+1.2%	$46.59M-0.9%	$47.02M+0.5%	$46.78M-15.5%
Total Equity Investments - Estimated Fair Value	$14.7M-2.4%	$15.07M-50.1%	$30.18M-7.6%	$32.66M+1.5%	$32.17M-33.9%
Accrued Progress Collections and Price Adjustments	$77.9M+3.6%	$75.18M+1.5%	$74.07M-0.7%	$74.57M-7.2%	$80.38M-18.6%
Contingent Consideration Liability (Non-Current)	$252K0.0%	$252K0.0%	$252K0.0%	$252K-92.1%	$3.18M-29.0%
Contract Liabilities, Non-Current	$77.9M+3.6%	$75.18M+1.5%	$74.07M-0.7%	$74.57M-7.2%	$80.38M-18.6%
Accrued expenses and other liabilities	$48.38M-27.2%	$66.46M-16.2%	$79.34M+38.6%	$57.23M-19.1%	$70.75M+8.2%
Deferred revenue, net of current portion	$77.9M+3.6%	$75.18M+1.5%	$74.07M-0.7%	$74.57M-7.2%	$80.38M-18.6%
Notes Payable - Fair Value	——	$7.13M—	——	——	——
Total debt	$410.7M-6.6%	$439.89M+4.0%	$422.87M-1.4%	$428.83M-1.3%	$434.56M-7.1%
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	65.1M+5.6%	61.7M+2.4%	60.3M+2.4%	58.8M+1.2%	58.1M+0.6%
Common Stock Shares Outstanding	$0—	——	$1.48M+145%	$605K—	$0—
Convertible Preferred Stock Authorized Shares	200M0.0%	200M0.0%	200M0.0%	200M0.0%	200M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—	0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$6K0.0%	$6K0.0%	$6K0.0%	$6K+20.0%	$5K0.0%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	$0—
Number of Exercisable Options	136K—	——	115.9K-28.6%	162.5K+494%	27.3K—
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Share-Based Payment Award Options Outstanding - Number	366.6K0.0%	366.6K0.0%	366.6K-15.4%	433.2K+65.8%	261.3K-2.3%
Weighted Average Exercise Price of Outstanding Options	$15.380.0%	$15.380.0%	$15.38-14.1%	$17.91-24.0%	$23.58-6.3%
Cumulative Cost Basis	$211.74M-10.5%	$236.64M-35.1%	$364.36M+6.5%	$342.22M-5.3%	$361.25M-0.9%
Accounts Receivable, after Allowance for Credit Loss	$454K+98.3%	$229K-75.3%	$929K-4.6%	$974K+11.1%	$877K+49.7%
Total	$211.74M-10.5%	$236.64M-35.1%	$364.36M+6.5%	$342.22M—	——
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five	$40.54M—	——	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five	$40.54M—	——	——	——	——
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One	$179.18M—	——	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One	$179.22M—	——	——	——	——
Available for sale investments	$229.59M-10.1%	$255.42M—	——	——	——
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$15.8B0.0%	$15.8B0.0%	$15.8B0.0%	$15.8B0.0%	$15.8B0.0%
Common stock, shares issued (in shares)	$65.13M+5.6%	$61.68M+2.4%	$60.26M+2.4%	$58.82M+1.2%	$58.15M+0.6%
Common Stock, Shares, Outstanding	$61.66M+5.9%	$58.21M+2.4%	$56.84M+2.5%	$55.43M+1.3%	$54.7M+0.6%
Contract with Customer, Asset, after Allowance for Credit Loss	$0—	$0—	$0—	$0—	$0—
Contract with Customer, Liability	——	$94.1M—	——	——	——
Trading securities, cost	$13.31M—	——	$27.81M—	——	——
Total initial cost	$109.46M—	——	$109.46M—	——	——
Current maturities of long-term debt	——	$20K—	——	——	——
Thereafter	$17.39M—	——	$20.59M+0.1%	$20.56M+9.6%	$18.76M—
2028	$2.94M—	——	$11.61M0.0%	$11.6M+2.3%	$11.34M—
2030	$2.94M—	——	$2.98M+0.1%	$2.98M+9.5%	$2.72M—
Remainder of 2026	$12.4M—	——	$4.67M-50.0%	$9.35M-34.4%	$14.24M—
2027	$10.24M—	——	$18.69M0.0%	$18.69M-1.5%	$18.98M—
2029	$2.94M—	——	$2.98M+0.1%	$2.98M+9.5%	$2.72M—
Loans Receivable Fair Value Disclosure	——	$500K—	——	——	——
Marketable Securities	$229.59M-10.1%	$255.42M-27.2%	$350.8M+29.9%	$270.13M+32.1%	$204.5M—
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$200M0.0%	$200M0.0%	$200M0.0%	$200M0.0%	$200M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—	$0—
Restricted cash equivalents included in Other long-term assets	$37.92M—	——	$37.09M+0.7%	$36.84M+5.1%	$35.04M—
Remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied	$127.4M-6.9%	$136.8M+68.3%	$81.3M-20.4%	$102.1M-17.5%	$123.8M+44.3%
Sale of stock, authorized amount	——	——	$100M—	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	$136.01K—	——	$115.93K-28.6%	$162.48K+494%	$27.34K—
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$366.57K0.0%	$366.57K0.0%	$366.57K-15.4%	$433.19K+65.8%	$261.31K-2.3%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$15.380.0%	$15.380.0%	$15.38-14.1%	$17.91-24.0%	$23.58-6.3%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	$0—	——	$1.48M+145%	$605K—	$0—
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$24.74—	——	$27.59-6.4%	$29.48-69.1%	$95.35—
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	$0—	——	$194K+113%	$91K—	$0—
Unbilled balances	$11.4M-21.4%	$14.5M+29.5%	$11.2M+2.8%	$10.9M—	——
Remainder of Fiscal Year 2024	$12.4M—	——	$4.67M-50.0%	$9.35M-34.4%	$14.24M—
Remainder of Fiscal Year 2025	$12.4M—	——	$4.67M-50.0%	$9.35M-34.4%	$14.24M—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Ginkgo Bioworks.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Ginkgo Bioworks's total assets?: Ginkgo Bioworks (DNA) holds $1.0B in total assets, down 20.1% year over year.
How much debt does Ginkgo Bioworks have?: Ginkgo Bioworks carries $410.7M in total debt against $443.2M of shareholders' equity, a debt-to-equity ratio of 0.93.
How much cash does Ginkgo Bioworks have?: Ginkgo Bioworks holds $188.7M in cash and equivalents.
Can Ginkgo Bioworks cover its short-term obligations?: Its current ratio is 5.15 — current assets exceed current liabilities.
Where does Ginkgo Bioworks's balance sheet data come from?: Every line is extracted from Ginkgo Bioworks's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.